

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Global Health Limited

ABN

75 091 377 892

We, Global Health Limited give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|--|--|
| 1 | +Class of +securities issued or to be issued | Ordinary shares and Share options |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | Maximum of approximately 127,459,848 fully paid ordinary shares under an offer to eligible shareholders and;

Maximum of approximately 118,636,319 share options under an offer to eligible shareholders |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares

Share options:
Exercise price: \$0.017
Expiry date: 31 December 2010 |

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

<p>4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>Yes</p>						
<p>5 Issue price or consideration</p>	<p>\$0.017 per ordinary share</p>						
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Ordinary Shares and Share Options issued pursuant to the forthcoming Renounceable Rights Issue for the purposes of:</p> <ul style="list-style-type: none"> - Investing in on-line sales and marketing channels; - Enhancing the capacity of post-sales deployment of the Company's e-health solutions and; - Providing working capital to allow the Company to more vigorously market its services in difficult economic times. 						
<p>7 Dates of entering +securities into uncertificated holdings or despatch of certificates</p>	<p>25 May 2009</p>						
<p>8 Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="721 1369 997 1400">Number</th> <th data-bbox="1002 1369 1261 1400">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="721 1404 997 1591"> 246,096,167 (being 118,636,319 + 127,459,848 ordinary shares fully paid as described in Part 2 above) and; </td> <td data-bbox="1002 1404 1261 1591"> Ordinary Shares </td> </tr> <tr> <td data-bbox="721 1627 997 1753"> 118,636,319 (being share options as described in Part 2 above) </td> <td data-bbox="1002 1627 1261 1753"> Options </td> </tr> </tbody> </table>	Number	+Class	246,096,167 (being 118,636,319 + 127,459,848 ordinary shares fully paid as described in Part 2 above) and;	Ordinary Shares	118,636,319 (being share options as described in Part 2 above)	Options
Number	+Class						
246,096,167 (being 118,636,319 + 127,459,848 ordinary shares fully paid as described in Part 2 above) and;	Ordinary Shares						
118,636,319 (being share options as described in Part 2 above)	Options						

+ See chapter 19 for defined terms.

9	Number and ⁺ class of all ⁺ securities not quoted on ASX (including the securities in clause 2 if applicable)	Number 5,466,667 share options	⁺ Class Unlisted share options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No	
12	Is the issue renounceable or non-renounceable?	Renounceable	
13	Ratio in which the ⁺ securities will be offered	1 to 1	
14	⁺ Class of ⁺ securities to which the offer relates	Ordinary shares and Share Options	
15	⁺ Record date to determine entitlements	19:00 EST - 3 June 2009	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A	
17	Policy for deciding entitlements in relation to fractions	Rounded up to the next whole share	
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	The offer is only made to shareholders with registered addresses in Australia and New Zealand. For shareholders with registered addresses in all other countries, a nominee will be appointed to arrange for the sale of the entitlements that would have been given to those shareholders and will account to them for the net proceeds of the sale.	
19	Closing date for receipt of acceptances or renunciations	17:00 EST - 23 June 2009	

⁺ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

20	Names of any underwriters	Bell Potter Securities Limited
21	Amount of any underwriting fee or commission	Management fee of \$20,168.17 plus an underwriting fee equal to 5% of the underwritten amount (equal to \$100,840.87)
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	9 June 2009
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	9 June 2009
28	Date rights trading will begin (if applicable)	28 May 2009
29	Date rights trading will end (if applicable)	16 June 2009
30	How do +security holders sell their entitlements <i>in full</i> through a broker?	By contacting their broker verbally or complete the section marked "In Full" on the Entitlement and Acceptance Form and lodging the form with their broker.
31	How do +security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	By completing the Entitlement and Acceptance Form in accordance with the instructions set out in the Entitlement and Acceptance Form, indicating the number of entitlement offer Shares the shareholder

+ See chapter 19 for defined terms.

wishes to accept (being less than their entitlement as specified on their Entitlement and Acceptance Form). Then return the completed Entitlement and Acceptance Form together with the full amount payable (being 1.7c multiplied by the number of Shares the shareholder wishes to accept under their entitlement).

32 How do +security holders dispose of their entitlements (except by sale through a broker)?

A standard renunciation must be used and may be obtained from a broker or the share registry.

33 +Despatch date

30 June 2009

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of securities
(tick one)

(a) Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over

+ See chapter 19 for defined terms.

Appendix 3B
New issue announcement

37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38 Number of securities for which +quotation is sought

39 Class of +securities for which quotation is sought

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42 Number and +class of all +securities quoted on ASX (including the securities in clause 38)		

+ See chapter 19 for defined terms.

Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:  Date: 27 May 2009
(Company secretary)

Print name: Peter Curigliano

====

+ See chapter 19 for defined terms.